Ankylosing Spondylitis Market Size, Share and Growth Outlook, 2026

Ankylosing Spondylitis Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Ankylosing Spondylitis Market size is forecast to increase from $6.49 Billion in 2026 to $10.74 Billion in 2034 at a CAGR of 6.5% between 2026 and 2034.

The Ankylosing Spondylitis market report provides detailed analysis and outlook of Ankylosing Spondylitis segments including By Drug Class (Tumor Necrosis Factor, Interleukin, Janus Kinase, Non-Steroidal Anti-Inflammatory Drugs, Disease-Modifying Anti-Rheumatic Drugs ), By Disease Stage (Early-Stage, Moderate Ankylosing Spondylitis, Severe), By Patient Type (Adult Ankylosing Spondylitis, Juvenile Ankylosing Spondylitis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies & Drugstores) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Ankylosing Spondylitis Industry Overview

Advances in Biologic Therapies Strengthening Autoimmune Disease Management

The ankylosing spondylitis industry continues to evolve through advancements in biologic therapies, expanding treatment options, and ongoing research focused on preventing long-term structural damage associated with chronic inflammatory diseases. As healthcare providers increasingly emphasize early intervention and disease modification, the development of targeted immune pathway therapies is reshaping the management of ankylosing spondylitis and related rheumatologic disorders. Innovations within the broader autoimmune disease treatment landscape are influencing therapeutic strategies aimed at controlling inflammation, preserving joint function, and improving patient quality of life. Growing scientific understanding of inflammatory pathways continues to drive the development of more precise and effective treatment approaches.

IL-23 Inhibition Reinforcing Disease Modification Strategies

A significant development within the autoimmune and rheumatology sector is the expansion of clinical evidence supporting interleukin-23 pathway inhibition. The U.S. Food and Drug Administration approved a supplemental Biologics License Application for TREMFYA® (guselkumab), incorporating evidence demonstrating inhibition of structural joint damage progression in patients with active Psoriatic Arthritis. Although the approved indication specifically addresses psoriatic arthritis, the findings hold substantial relevance for the ankylosing spondylitis market because both conditions share overlapping inflammatory mechanisms and treatment approaches. The expanded clinical evidence strengthens confidence in targeted biologic therapies designed to prevent irreversible joint destruction and supports ongoing interest in immune-modulating treatments capable of delivering long-term disease control across rheumatologic disorders.

Biosimilar Competition Expanding Treatment Accessibility

The ankylosing spondylitis treatment landscape is also being influenced by the continued development of biosimilar therapies. Bio-Thera Solutions is advancing BAT2506, a proposed biosimilar candidate to golimumab, the active component of Simponi, which is an established therapy for ankylosing spondylitis. If approved, BAT2506 would become the first golimumab biosimilar available in the market, introducing additional treatment options for healthcare providers and patients. The emergence of biosimilars is expected to enhance treatment accessibility, support broader patient access to advanced biologic therapies, and encourage competitive dynamics within the autoimmune disease treatment sector. Growing biosimilar development activity reflects a broader industry effort to expand availability of high-quality biologic treatments while addressing long-term healthcare affordability and patient access considerations.

Ankylosing Spondylitis Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Ankylosing Spondylitis market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson (Janssen), Pfizer Inc., Eli Lilly and Company, UCB S.A., Bristol-Myers Squibb Company, Merck & Co., Inc., Biogen Inc.. The Ankylosing Spondylitis market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Ankylosing Spondylitis industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Ankylosing Spondylitis Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Ankylosing Spondylitis companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Ankylosing Spondylitis markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Ankylosing Spondylitis Market Competitive Benchmarking and Company Analysis

Leading companies in Ankylosing Spondylitis industry include- AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson (Janssen), Pfizer Inc., Eli Lilly and Company, UCB S.A., Bristol-Myers Squibb Company, Merck & Co., Inc., Biogen Inc.. The Ankylosing Spondylitis market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Ankylosing Spondylitis Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Ankylosing Spondylitis market remains one of the strongest-performing segments in the country.
The US Ankylosing Spondylitis Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Ankylosing Spondylitis market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Ankylosing Spondylitis industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Ankylosing Spondylitis markets

Canada's strong Ankylosing Spondylitis sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Ankylosing Spondylitis market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Ankylosing Spondylitis Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Ankylosing Spondylitis market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Ankylosing Spondylitis population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Ankylosing Spondylitis industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Ankylosing Spondylitis market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Ankylosing Spondylitis sales through 2034

France Ankylosing Spondylitis companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Ankylosing Spondylitis Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Ankylosing Spondylitis distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Ankylosing Spondylitis Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Ankylosing Spondylitis market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Ankylosing Spondylitis industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Ankylosing Spondylitis industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Ankylosing Spondylitis Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Ankylosing Spondylitis market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Ankylosing Spondylitis market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Ankylosing Spondylitis Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Ankylosing Spondylitis Market Segmentation

By Drug Class
Tumor Necrosis Factor
Interleukin
Janus Kinase
Non-Steroidal Anti-Inflammatory Drugs
Disease-Modifying Anti-Rheumatic Drugs
By Disease Stage
Early-Stage
Moderate Ankylosing Spondylitis
Severe
By Patient Type
Adult Ankylosing Spondylitis
Juvenile Ankylosing Spondylitis
By Distribution Channel
Hospital Pharmacies
Specialty Pharmacies
Retail Pharmacies & Drugstores

Top Companies in Ankylosing Spondylitis Industry

AbbVie Inc.
Amgen Inc.
Novartis AG
Johnson & Johnson (Janssen)
Pfizer Inc.
Eli Lilly and Company
UCB S.A.
Bristol-Myers Squibb Company
Merck & Co., Inc.
Biogen Inc.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa